RESEARCH miR-148b reverses cisplatin t e

Lung cancer is regarded as the leading cause of cancer related deaths worldwide [1]. Among this, non-small cell lung cancer (NSCLC), which distinguished to small-cell lung cancer (SCLC) from pathological and histological characteristics, represents approximately 85 % [2] and its five-year survival is only 15 % [3]. Chemotherapy is well known as the main method to treat lung cancer in earlier stages of treatment, especially as adjuvant chemotherapy after surgery. Although advances in cisplatin-based chemotherapy have resulted in improving the rate of survival, their therapeutic efficacy was limited for the development of cisplatin resistance. Therefore, a good understanding of the molecular mechanisms underlying cisplatin resistance development is urgently needed. microRNAs are small non-coding RNA molecules con-sisting of 20–24 nucleotides and function as the sup-pressor for gene expression by interacting with the 3′-untranslated regions (3′UTRs) of target mRNAs at 5–7 nucleotides. These interactions may lead to either ob-struction of translation or degradation of the targete